Compound ID | 2881
APT-CF phage (WRAIR-PAM-CF1)
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Natural product; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-negative |
| Target Pathogen: | Active against Pseudomonas aeruginosa |
| Description: | A IV phage therapy for cystic fibrosis patients; a mixture which consists of four antipseudomonal phages |
| Institute where first reported: | Adaptive Phage Therapeutics |
| Year first mentioned: | 2022 |
| Highest development stage: | Phase 2 (NCT05453578) |
| Development status: | Active as of 2024 |
| External links: | |
| Citation: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795609/pdf/13063_2022_Article_7047.pdf |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.